ArticleOncology letters2017
Azithromycin attenuates acute radiation-induced lung injury in mice.
Article in Oncology letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- Ionizing radiation: molecular mechanisms, biological effects, and therapeutic targets.Molecular biomedicine · 2026Review
- Reducing radiation pneumonitis in lung cancer patients: from Chinese expert consensus to practice.Translational lung cancer research · 2025Article
- Effects of azithromycin on lung oxidative injury and immune function in mice infected withCentral-European journal of immunology · 2025Article
- Pathological and pharmacovigilance monitoring as toxicological imputations of azithromycin and its residues in broilers.Veterinary world · 2024Article
- Immunomodulatory role of azithromycin: Potential applications to radiation-induced lung injury.Frontiers in oncology · 2023Review
- Exploration of radiation-induced lung injury, from mechanism to treatment: a narrative review.Translational lung cancer research · 2022Review
- Antibiotics as immunomodulators: a potential pharmacologic approach for ARDS treatment.European respiratory review : an official journal of the European Respiratory Society · 2021Review
- Knockdown of long non‑coding RNA DLEU2 suppresses idiopathic pulmonary fibrosis by regulating the microRNA‑369‑3p/TRIM2 axis.International journal of molecular medicine · 2021Article
- COVID-19 in Elderly Adults: Clinical Features, Molecular Mechanisms, and Proposed Strategies.Aging and disease · 2020Review
- Can COVID 2019 induce a specific cardiovascular damage or it exacerbates pre-existing cardiovascular diseases?Pathology, research and practice · 2020Review
- IL-6: Relevance for immunopathology of SARS-CoV-2.Cytokine & growth factor reviews · 2020Review
- Article
- Review
- An investigation of the effects of N-acetylcysteine on radiotherapy-induced testicular injury in rats.Naunyn-Schmiedeberg's archives of pharmacology · 2019Article
- Cryptotanshinone Ameliorates Radiation-Induced Lung Injury in Rats.Evidence-based complementary and alternative medicine : eCAM · 2019Article
- Article
- Cytokines and radiation-induced pulmonary injuries.Journal of radiation research · 2018Review
- Azithromycin Promotes the Osteogenic Differentiation of Human Periodontal Ligament Stem Cells after Stimulation with TNF-Stem cells international · 2018Article
- The value of macrolides in the adjuvant treatment of pulmonary fibrosis: maybe a panacea.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Radiation-induced lung injury (RILI) is a common and major obstacle in thoracic cancer radiotherapy, resulting in considerable morbidity and limiting the dose of radiation. However, an effective treatment option remains to be established. Therefore, the present study aimed to investigate the effects of azithromycin (AZM) in acute RILI with a mouse model. In the present study, C57BL/6 mice were given a single thoracic irradiation of 16 Gy and administered orally with AZM. The lung histopathological findings, the levels of malondialdehyde (MDA; an indicator of oxidative damage) and the concentration of pro-inflammatory and pro-fibrotic cytokines in plasma were assessed on 28 day following irradiation. In addition, the total cell counts in bronchoalveolar lavage fluid (BALF), the pro-inflammatory and pro-fibrotic cytokine gene expression in lung tissue were evaluated on day 7, 14 and 28 following irradiation. Administration with AZM markedly alleviated acute RILI as indicated by hematoxylin and eosin and Masson staining. The levels of MDA and total cell counts in BALF significantly reduced in AZM treated mice. AZM also down-regulated the concentration and mRNA expression of interleukin (IL)-1β, IL-6, tumor necrosis factor-α and transforming growth factor-β1. In addition, AZM attenuated the irradiation-induced increases in the mRNA expression of fibrotic markers (α-smooth muscle actin and α-1 type I collagen). AZM treatment mitigated the radiation-induced acute lung injury possibly by its anti-inflammatory and anti-fibrotic effects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.